Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model

Lignende værker

• Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
  af: Masuda, Chinami, et al.
  Udgivet: (2017)
• Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model
  af: Ishikura, Nobuyuki, et al.
  Udgivet: (2019)
• Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies
  af: Iwai, Toshiki, et al.
  Udgivet: (2018)
• Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model
  af: HARADA, SUGURU, et al.
  Udgivet: (2015)
• Biomarkers for antitumor activity of bevacizumab in gastric cancer models
  af: Yamashita-Kashima, Yoriko, et al.
  Udgivet: (2012)